Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4basebio Plc Regulatory News (4BB)

Share Price Information for 4basebio Plc (4BB)

Share Price is delayed by 15 minutes
Get Live Data
547.50    0.00 (0.00%)
Bid:
520.00
Ask:
575.00
Spread: 55.00 (10.577%)
Market Cap: £84.78m
4BB Live PriceLast checked at - London Stock Exchange

Intraday 4basebio Plc Share Chart

Holding(s) in Company

17 Jun 2025 07:00

4basebio Plc - Holding(s) in Company

4basebio Plc - Holding(s) in Company

PR Newswire

LONDON, United Kingdom, June 17

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMCLYF79

Issuer Name

4BASEBIO PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Wilhelm K. T. Zours

City of registered office (if applicable)

Heidelberg

Country of registered office (if applicable)

Germany

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

09-Jun-2025

6. Date on which Issuer notified

13-Jun-2025

7. Total positions of person(s) subject to the notification obligation

. % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached 33.013179 0.000000 33.013179 5115852
Position of previous notification (if applicable) 32.764383 0.000000 32.764383

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
GB00BMCLYF79 5115852 33.013179
Sub Total 8.A 5115852 33.013179%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Wilhelm K.T. Zours
Wilhelm K.T. Zours DELPHI Unternehmensberatung Aktiengesellschaft 4.119901 4.119901%
Wilhelm K.T. Zours VV Beteiligungen Aktiengesellschaft
Wilhelm K.T. Zours Deutsche Balaton Aktiengesellschaft
Wilhelm K.T. Zours SPARTA AG
Wilhelm K.T. Zours SPARTA Invest AG 8.722791 8.722791%
Wilhelm K.T. Zours 2invest AG 14.384528 14.384528%
Wilhelm K.T. Zours Latonba AG 5.090546 5.090546%

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

13. Place Of Completion

Heidelberg, Germany



Date   Source Headline
22nd May 20269:10 amPRNDirector Dealing
20th May 20267:02 amPRNFinal Results and Notice of AGM
20th May 20267:00 amPRN4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
14th May 20267:00 amPRNAppointment of Chief Financial Officer and Board Changes
11th May 20267:00 amPRN4basebio Launches Enzymatic ssDNA Platform
31st Mar 20267:00 amPRNLease of Manufacturing Facility
12th Mar 20267:00 amPRNAppointment of COO
3rd Mar 20267:00 amPRNAppointment of CCO
16th Feb 20267:00 amPRNDirector Dealing
11th Feb 20263:58 pmPRNDirector Dealing
10th Feb 20267:00 amPRNLeadership Changes
27th Oct 20257:00 amPRNSynthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 202511:30 amPRNResult of Extraordinary General Meeting
30th Sep 20254:20 pmPRNDirector Dealing
29th Sep 20257:00 amPRNHalf-year Report
22nd Jul 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
8th Jul 202510:30 amPRNDirector Appointment, Board Change
3rd Jul 20257:00 amPRNHolding(s) in Company
3rd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
27th Jun 20256:05 pmPRNResult of AGM
25th Jun 20257:00 amPRNExercise of Options
17th Jun 20257:00 amPRNHolding(s) in Company
17th Jun 20257:00 amPRNHolding(s) in Company
27th May 20257:00 amPRNFinal Results and Notice of AGM
4th Apr 202512:00 pmPRNDirector Dealing
2nd Apr 20257:00 amPRN4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
25th Mar 202510:15 amPRNHolding(s) in Company
14th Mar 20257:00 amPRNRBC Capital Markets initiates research coverage
7th Mar 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
3rd Mar 20254:37 pmPRNDirector's Dealing
8th Jan 20257:00 amPRNAppointment of Chief Commercial Officer
17th Dec 20247:00 amPRNDirectorate Change
29th Nov 202412:30 pmPRNDirector's Dealing
19th Nov 20242:15 pmPRNDirector's Dealing
15th Nov 20245:31 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20247:00 amPRNHolding(s) in Company
14th Nov 20247:00 amPRNAppointment of Joint Corporate Broker
12th Nov 20247:00 amPRNCompletion of Strategic Investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.